Fig. 3: Synthetic-SVV is efficacious in the presence of circulating SVV-neutralizing antibodies. | Nature Communications

Fig. 3: Synthetic-SVV is efficacious in the presence of circulating SVV-neutralizing antibodies.

From: Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

Fig. 3

Anti-tumor efficacy of Synthetic SVV-derived virus SVV(S177A-IRES2) and Synthetic-SVV as assessed by tumor volume (mm3) was evaluated in NCI-H446 tumor bearing mice after injection of control or neutralizing anti-SVV rabbit serum. Mice that were passively immunized with SVV antisera received 3 IV injections of either 106 PFU of SVV(S177A-IRES2) virions or 0.1 mg/kg Synthetic-SVV (n = 10 per group). Data are presented as mean values +/− SEM. Statistical significance was determined using a mixed linear model. p < 0.001 vs PBS, SVV(S177A-IRES2) & Control Ab. Source data are provided as a Source Data file.

Back to article page